Partner Content Partner Content 3 things you should know about ADaM standards Digging deeper into the Analysis Data Model (ADaM)
Partner Content Partner Content Using SDTM, ADaM, and SEND for Regulatory Submissions Using SDTM, ADaM, and SEND for Regulatory Submissions
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
